Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers

Clinical and Vaccine Immunology

Volumn 18, Issue 12, 2011, Pages 2136-2142

  Riddle, Valerie ^a   Leese, Phillip ^b   Blanset, Diann ^c,d   Adamcio, Melany ^a   Meldorf, Matthew ^a,e   Lowy, Israel ^c,f  

^a PharmAthene Inc   (United States)

^b IQVIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e GENENTECH INC   (United States)

^f REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; MDX 1303; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VALORTIM;

ADULT; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE PAIN; MALE; NONHUMAN; NORMAL HUMAN; NOSE CONGESTION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SERODIAGNOSIS; SINGLE DRUG DOSE; SORE THROAT; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANTHRAX; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; ANTITOXINS; BACTERIAL TOXINS; HALF-LIFE; HUMAN EXPERIMENTATION; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS;

EID: 83455259467     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05059-11     Document Type: Article

References (18)

1. Abramova, F. A., L. M. Grinberg, O. V. Yampolskaya, and D. H. Walker. 1993. Pathology of inhalational anthrax in 42 cases from the Sverdlosk outbreak of 1979. Proc. Natl. Acad. Sci. U. S. A. 90:2291-2294. (Pubitemid 23078612)
2. Christopher, G. W., J. Cieslak, J. A. Pavlin, E. M. Eitzen, Jr. 1997. Biological warfare: a historical perspective. JAMA 278:412-417. (Pubitemid 27327460)
3. Dixon, T. C., M. Meselson, J. Guillemin, and P. C. Hanna. 1999. Anthrax. N. Engl. J. Med. 341:815-826. (Pubitemid 29420478)
4. Edmeads, J., et al. 1993. Impact of migraine and tension-type headache on lifestyle, consulting behavior, and medication use: a Canadian population survey. Can. J. Neurol. Sci. 20:131-137. (Pubitemid 23212865)
5. Executive Action, LLC. 2007. Spores: the threat of a catastrophic anthrax attack on America. Signature Book Printing, Gaithersburg, MD.
6. FDA. 2009. Draft guidance for industry: animal models - essential elements to address efficacy under the Animal Rule. http://www.fda.gov/cder/ guidance/index.htm. Accessed 31 March 2009.
7. Friedlander, A. M. 2000. Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr. Clin. Top. Infect. Dis. 20:335-349.
8. Hansen, J. 1986. Older maternal age and pregnancy outcome: a review of the literature. Obstet. Gynecol. Surv. 41:726-742.
9. Inglesby, T. V., et al. 1999. Anthrax as a biological weapon: medical and public health management. JAMA 281:1735-1745. (Pubitemid 29226485)
10. Inglesby, T. V., et al. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252. (Pubitemid 34441940)
11. Jernigan, J., et al. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933-943.
12. Mandell, G. L., J. E. Bennet, and R. Dolin (ed.). 2000. Principles and practice of infectious diseases, 5th ed., p. 1887-1888. Churchill-Livingstone, New York, NY.
13. Rasmussen, B. K., R. Jensen, M. Schroll, and J. Olesen. 1991. Epidemiology of headache in a general population: a prevalence study. J. Clin. Epidemiol. 44:1147-1157.
14. Swartz, M. N. 2001. Recognition and management of anthrax-an update. N. Engl. J. Med. 345:1621-1626.
15. Thavendiranathan, P., A. Bagai, A. Ebidia, A. S. Detsky, and N. K. Choudhry. 2005. Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels. J. Gen. Intern. Med. 20:520-524. (Pubitemid 41003807)
16. Tierney, B., et al. 2003. Serious adverse events among participants in the Centers for Disease Control and Prevention's anthrax vaccine and antimicrobial availability program for persons at risk for bioterrorism-related inhalational anthrax. Clin. Infect. Dis. 37:905-911. (Pubitemid 37267204)
17. Vitale, L., et al. 2006. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect. Immun. 74:5840-5847. (Pubitemid 44484571)
18. Young, J. T., and R. J. Collier. November 2003. Attacking anthrax. Scientific American Exclusive Online Issue, p. 26-32.